SCHEMBL6324864

SCHEMBL6324864

CCOc1ccc(S(=O)(=O)N(C)[C@H](C)CS)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
POLB P06746 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
CNR2 P34972 1/20 0.44
LMNA P02545 3/20 0.44
HTT P42858 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ADAM17 P78536 4/20 0.43
HPGD P15428 2/20 0.43
MMP13 P45452 3/20 0.43
MMP1 P03956 2/20 0.43
MMP9 P14780 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324860 1.00 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL6325750 0.89 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL6325747 0.89 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL6323349 0.86 MMP3 (0.51) CA12CA1CA2CA7CA9
SCHEMBL6323355 0.86 MMP3 (0.51) CA12CA1CA2CA7CA9
SCHEMBL22104936 0.86 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL6330960 0.85 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL6330962 0.85 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL6323218 0.85 MEN1 (0.61) POLBMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6323221 0.85 MEN1 (0.61) POLBMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CA12 248/4885CA1 196/4885CA2 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.